Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

By |2023-10-23T11:57:48+00:00October 23rd, 2023|News|

Study is designed to evaluate the safety and tolerability of increasing dose levels of the